Showing 17,361 - 17,380 results of 46,043 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 1.35s Refine Results
  1. 17361
  2. 17362
  3. 17363

    RICTOR silencing inhibits cell proliferation via UGCG regulation. by Mohammad Nafees Ansari (22232505)

    Published 2025
    “…(<b>F</b>) Fold change (mean ± SEM, <i>n</i> = 5) in different sphingolipid species reveals an increase in ceramides and a decrease in glucosylceramides in MCF-7_RICTOR<sup>SH</sup> cells compared to MCF-7 cells. …”
  4. 17364

    Mechanical Behavior of a Novel Nanocomposite Polysulphone - Carbon Nanotubes Membrane for Water Treatment by Wang, Kui

    Published 2016
    “…Uniaxial tensile behavior of the membranes was characterized by means of a universal material testing machine under different testing conditions. …”
    Get full text
    Get full text
  5. 17365
  6. 17366
  7. 17367
  8. 17368
  9. 17369

    Cilostazol inhibits endothelin-induced calcium increase and vasoconstriction in mouse intracranial arteries. a. by Yoshifumi Kawanabe (308848)

    Published 2013
    “…Arrows denote basilar artery constriction. Bar = 50 µm <b>c.</b> Cilostazol significantly decreases endothelin-induced cytosolic calcium increase. …”
  10. 17370
  11. 17371

    The in vitro and in vivo effect of a chemokine inhibitor CTCE-9908 in combination with Kynurenine metabolites on tumour adhesion by Danielle Tatchum (16946574)

    Published 2025
    “…In the non-cancerous cell lines HaCaT and EA. hy926, there was a decrease in percentage cell number after treatment with L-kyn, phorbol 12-myristate 13-acetate (PMA), a positive control for adhesion, and CTCE-9908, suggesting a decrease in cell adhesion in the non-cancerous cell lines.…”
  12. 17372

    Cervical Cancer Screening in Partly HPV Vaccinated Cohorts – A Cost-Effectiveness Analysis by Steffie K. Naber (2175986)

    Published 2016
    “…</p><p>Methods</p><p>We used the MISCAN-Cervix model to determine the optimal screening strategy for a pre-vaccination population and for vaccinated women (~80% decreased risk), assuming a willingness-to-pay of €50,000 per quality-adjusted life year gained. …”
  13. 17373
  14. 17374
  15. 17375

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  16. 17376

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  17. 17377

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  18. 17378
  19. 17379
  20. 17380